Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2020 | Updated results from BELLINI: venetoclax with bortezomib/dexamethasone

Shaji Kumar • 1 Jun 2020
ASCO 2020
Multiple Myeloma Bortezomib Dexamethasone Venetoclax
BELLINI

Shaji Kumar, MD, Mayo Clinic, Rochester, MN, outlines the updated results from the BELLINI trial (NCT02755597), a Phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory (R/R) multiple myeloma (MM). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Shaji Kumar

Long-term efficacy and safety of etentamig, a BCMA bispecific antibody, in R/R multiple myeloma
3:00
Long-term efficacy and safety of etentamig, a BCMA bispecific antibody, in R/R multiple myeloma
Shaji Kumar • 17 Jun 2025
Long-term outcomes from the ENDURANCE trial: VRd versus KRD in newly diagnosed myeloma
2:37
Long-term outcomes from the ENDURANCE trial: VRd versus KRD in newly diagnosed myeloma
Shaji Kumar • 17 Jun 2025
The feasibility of outpatient strategies for treating multiple myeloma with bispecifics and CAR-T
1:57
The feasibility of outpatient strategies for treating multiple myeloma with bispecifics and CAR-T
Shaji Kumar • 17 Jun 2025
RedirecTT-1: the safety and efficacy of talquetamab and teclistamab in R/R multiple myeloma with EMD
5:43
RedirecTT-1: the safety and efficacy of talquetamab and teclistamab in R/R multiple myeloma with EMD
Shaji Kumar • 17 Jun 2025

Related Videos

Impact of Duffy status on PFS in newly diagnosed multiple myeloma treated with RVd ± autoSCT
4:13
Impact of Duffy status on PFS in newly diagnosed multiple myeloma treated with RVd ± autoSCT
Shaji Kumar • 7 Dec 2025
Key multiple myeloma breakthroughs at ASH 2025
6:04
Key multiple myeloma breakthroughs at ASH 2025
Shaji Kumar • 7 Dec 2025
A dual-targeting BCMA and CD19 FasTCAR-T (GC012F/AZD0120) as 1L therapy for newly diagnosed myeloma
4:18
A dual-targeting BCMA and CD19 FasTCAR-T (GC012F/AZD0120) as 1L therapy for newly diagnosed myeloma
Shaji Kumar • 7 Dec 2025
Ultra-deep WGS of cell-free DNA to detect bone marrow-derived mutations in multiple myeloma
2:29
Ultra-deep WGS of cell-free DNA to detect bone marrow-derived mutations in multiple myeloma
Shaji Kumar • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals